NCT03090659View on ClinicalTrials.gov

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 2, 2015

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Refractory or Relapsed Multiple Myeloma
Interventions
BIOLOGICAL

LCAR-B38M CAR-T cell injection

Sponsors
All Listed Sponsors
collaborator

Second Affiliated Hospital of Xi'an Jiaotong University

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

Jiangsu Provincial People's Hospital

OTHER

collaborator

Shanghai Changzheng Hospital

OTHER

lead

Nanjing Legend Biotech Co.

INDUSTRY